NCEL
HEALTHCARENLS Pharmaceutics Ltd
$3.32-0.27 (-7.52%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NCEL Today?
No stock-specific AI insight has been generated for NCEL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.83$30.80
$3.32
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-2.16
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume80K
Avg Volume (10D)—
Shares Outstanding5.3M
NCEL News
17 articles- Despite NewcelX's Pullback, Insiders Still Gained ₪136kYahoo Finance·May 1, 2026
- NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026Yahoo Finance·Apr 30, 2026
- NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceYahoo Finance·Apr 20, 2026
- NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingYahoo Finance·Apr 1, 2026
- NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesYahoo Finance·Mar 9, 2026
- NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization StrategyYahoo Finance·Feb 12, 2026
- NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering ConferencesYahoo Finance·Jan 29, 2026
- NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune SuppressionYahoo Finance·Jan 12, 2026
- NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory BoardYahoo Finance·Jan 5, 2026
- NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaYahoo Finance·Dec 11, 2025
- Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsightYahoo Finance·Dec 2, 2025
- NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstituteYahoo Finance·Nov 17, 2025
- NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardYahoo Finance·Nov 6, 2025
- NewcelX CEO Issues Letter to ShareholdersYahoo Finance·Nov 4, 2025
- NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.Yahoo Finance·Nov 3, 2025
- Owning 58% in NewcelX Ltd. (NASDAQ:NCEL) means that insiders are heavily invested in the company's futureYahoo Finance·Nov 1, 2025
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerYahoo Finance·Oct 30, 2025
All 17 articles loaded
Price Data
Open$3.54
Previous Close$3.59
Day High$3.73
Day Low$3.20
52 Week High$30.80
52 Week Low$1.83
52-Week Range
$1.83$30.80
$3.32
Fundamentals
Market Cap$18M
P/E Ratio—
EPS$-2.16
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume80K
Avg Volume (10D)—
Shares Outstanding5.3M
About NLS Pharmaceutics Ltd
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—